Sazgarnia Soudabeh, Layegh Pouran, Darchini-Maragheh Emadodin, Sepehr Vahid, Meshkat Mojtaba, Fathi-Najafi Sedigheh, Rahsepar Sara
Emadodin Darchini-Maragheh, MD, Mashhad University of Medical Sciences, Mashhad, Iran;
Acta Dermatovenerol Croat. 2022 Nov;30(3):146-150.
Vitiligo is a recalcitrant depigmentary autoimmune skin disorder. Hydroxychloroquine (HCQ) is an effective immunomodulatory drug which is widely used in treatment of autoimmune disorders. HCQ-induced pigmentation has been previously found in patients taking HCQ due to other autoimmune diseases. The present study aimed to determine whether HCQ improves re-pigmentation of generalized vitiligo. HCQ was orally administered 400 mg daily (6.5 mg/Kg of body weight) by 15 patients with generalized vitiligo (more than 10% involvement of body surface area) for three months. Patients were evaluated monthly and skin re-pigmentation was assessed using the Vitiligo Area Scoring Index (VASI). Laboratory data were obtained and repeated monthly. Fifteen patients (12 women and 3 men) with a mean age of 30.13±12.75 years were studied. After 3 months, the extent of re-pigmentation on all the body regions, including the upper extremities, hands, trunk, lower extremities, feet, and head and neck was significantly higher than the baseline (P value <0.001, 0.016, 0.029, <0.001, 0.006, 0.006, respectively). Patients with concomitant autoimmune diseases had significantly more re-pigmentation compared with others (P=0.020). No irregular laboratory data were observed during the study. HCQ could be an effective treatment for generalized vitiligo. The benefits are likely to be more evident in case of concomitant autoimmune disease. The authors recommend additional large-scale controlled studies to draw further conclusions.
白癜风是一种顽固性色素脱失性自身免疫性皮肤病。羟氯喹啉（HCQ）是一种有效的免疫调节药物，广泛用于治疗自身免疫性疾病。先前已发现因其他自身免疫性疾病服用HCQ的患者出现HCQ诱导的色素沉着。本研究旨在确定HCQ是否能改善泛发性白癜风的色素再生。15例泛发性白癜风（体表面积受累超过10%）患者口服HCQ，每日400mg（6.5mg/kg体重），持续3个月。每月对患者进行评估，并使用白癜风面积评分指数（VASI）评估皮肤色素再生情况。每月获取并重复实验室数据。研究了15例患者（12名女性和3名男性），平均年龄为30.13±12.75岁。3个月后，包括上肢、手部、躯干、下肢、足部以及头颈部在内的所有身体部位的色素再生程度均显著高于基线水平（P值分别<0.001、0.016、0.029、<0.001、0.0
